#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Vaccination against Covid-19 - IgG antibodies, CIC and complement components in serum


Authors: K. Absolonová;  M. Hill;  I. Šterzl
Authors place of work: Vedoucí laboratorního komplementu: Mgr. Josef Včelák ;  Endokrinologický ústav, Praha
Published in the journal: Prakt. Lék. 2024; 104(3): 112-115
Category: Of different specialties

Summary

In a group of vaccinated and unvaccinated individuals who did or did not experience Covid-19 disease, we monitored the relationship between anti-SARS-CoV-2 IgG and some parameters that, according to the literature, are important in the development and course of illness of Covid-19. These were total IgG, IgG1-4 subclasses, complement components C3c, C4 and circulating immune complexes (CIC). We found that unvaccinated, vaccinated with Pfizer/BioNTech and Moderna vaccine, as well as advanced and non-advanced Covid-19 patients differed significantly in the level of anti-SARS-CoV-2 IgG. Vaccination had a greater effect on the level of antibodies than experiencing the disease. IgG4 increased in vaccinees after the Pfizer/BioNTech vaccine. Other IgG subclasses, total IgG, CIC and complement components were not statistically significantly different between groups.

Keywords:

vaccination – COVID-19 – IgG – complement components – circulating immune complexes


Zdroje
  1. Dispenza MC. Classification of hypersensitivity reactions. Allergy Asthma Proc. 2019; 40(6): 470–473.
  2. Dobiáš M, Lami J, Bukovská L, Kořínek, J. Imunotrombóza, koagulopatie, plicní embolie a její diagnostika u COVID-19. AtheroRev. 2022; 7(1): 6–13.
  3. Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients with severe Covid-19. Nat Immunol. 2021; 22(1): 67–73.
  4. Irrgang P, Gerling J, Kocher K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARSCoV-2 mRNA vaccination. Sci Immunol. 2023; 8(79): eade2798.
  5. Jarlhelt I, Nielsen SK, Jahn CXH, et al. SARS-CoV-2 Antibodies mediate complement and cellular driven inflammation. Front Immunol. 2021; 12: 767981.
  6. Manzo G. Covid-19 as an immune complex hypersensitivity in antigen excess conditions: theoretical pathogenetic process and suggestions for potential therapeutic interventions. Front Immunol. 2020; 11: 566000.
  7. Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of Covid-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020; 215: 108450.
  8. Mücke T, Knop V, Mücke MM, et al. First description of immune complex vasculitis after Covid-19 vaccination with BNT162b2: a case report. BMC Infect Dis. 2021; 21: 958.
  9. Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in Covid-19 vasculitis. Clin Immunol. 2020; 217: 108487.
  10. Vaquero ST, de Campos-Mata L, Ramada JM, et al. The mRNA-1273 Vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity. Front Immunol. 2021; 12: 737083.

adresa pro korespondenci:
Mgr. Karolína Absolonová, PhD.
Endokrinologický ústav
Národní 8, 110 00 Praha 1
e-mail:
kabsolonova@endo.cz

Štítky
General practitioner for children and adolescents General practitioner for adults

Článok vyšiel v časopise

General Practitioner

Číslo 3

2024 Číslo 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#